For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Oral Erlotinib and Pulsed Doses of Oral AT-101 | Treatment-naïve advanced (Wet Stage IIIB and IV)NSCLC patients with EGFR activating mutations. | None | None | 1 | 5 | 5 | 5 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Hypotension | SYSTEMATIC_ASSESSMENT | Cardiac disorders | CTC-3.0 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| ALT, SGPT | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | CTC-3.0 | View |
| AST, SGOT | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | CTC-3.0 | View |
| Diarrhea | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | CTC-3.0 | View |
| Fatigue (asthenia, lethargy, malaise) | SYSTEMATIC_ASSESSMENT | General disorders | CTC-3.0 | View |
| Nausea | SYSTEMATIC_ASSESSMENT | General disorders | CTC-3.0 | View |
| Neutrophils/granulocytes | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | CTC-3.0 | View |